{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:04:07Z","timestamp":1792785847495,"version":"4.5.0"},"reference-count":34,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2019,7,25]],"date-time":"2019-07-25T00:00:00Z","timestamp":1564012800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["089276\/B\/09\/7"],"award-info":[{"award-number":["089276\/B\/09\/7"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ExxonMobil Global Health"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The Global Programme to Eliminate Lymphatic Filariasis (GPELF) was launched in 2000 with the goal of eliminating lymphatic filariasis (LF) as a public health problem by 2020. Despite considerable progress, the current prevalence is around 60% of the 2000 figure, with the deadline looming a year away. Consequently, there is a continued need for investment in both the mass drug administration (MDA) and morbidity management programs, and this paper aims to demonstrate that need by estimating the health and economic burdens of LF prior to MDA programs starting in GPELF areas.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A previously developed model was used to estimate the numbers of individuals infected and individuals with symptomatic disease, along with the attributable number of disability-adjusted life years (DALYs). The economic burden was calculated by quantifying the costs incurred by the health-care system in managing clinical cases, the patients\u2019 out-of-pocket costs, and their productivity costs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Prior to the MDA program, approximately 129 million people were infected with LF, of which 43 million had clinical disease, corresponding to a DALY burden of 5.25 million. The average annual economic burden per chronic case was US $115, the majority of which resulted from productivity costs. The total economic burden of LF was estimated at US $5.8 billion annually.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These results demonstrate the magnitude of the LF burden and highlight the continued need to support the GPELF. Patients with clinical disease bore the majority of the economic burden, but will not benefit much from the current MDA program, which is aimed at reducing transmission. This assessment further highlights the need to scale up morbidity management programs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciz671","type":"journal-article","created":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T07:22:12Z","timestamp":1563520932000},"page":"2561-2567","source":"Crossref","is-referenced-by-count":58,"title":["The Health and Economic Burdens of Lymphatic Filariasis Prior to Mass Drug Administration Programs"],"prefix":"10.1093","volume":"70","author":[{"given":"Christopher G","family":"Mathew","sequence":"first","affiliation":[{"name":"Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison A","family":"Bettis","sequence":"first","affiliation":[{"name":"London Centre for Neglected Tropical Disease Research, Imperial College London, United Kingdom"},{"name":"Department of Infectious Disease Epidemiology, School of Public Health, Faculty of Medicine, St Marys Campus, Imperial College London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian K","family":"Chu","sequence":"first","affiliation":[{"name":"Neglected Tropical Diseases Support Center, Task Force for Global Health, Decatur, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"English","sequence":"first","affiliation":[{"name":"Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, United Kingdom"},{"name":"Kenya Medical Research Institute, Wellcome Trust Research Programme, Nairobi"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric A","family":"Ottesen","sequence":"first","affiliation":[{"name":"Neglected Tropical Diseases Support Center, Task Force for Global Health, Decatur, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark H","family":"Bradley","sequence":"first","affiliation":[{"name":"Global Health Programs, GlaxoSmithKline, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo C","family":"Turner","sequence":"first","affiliation":[{"name":"Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, United Kingdom"},{"name":"Oxford University Clinical Research Unit, Wellcome Africa Asia Programme, Ho Chi Minh City, Vietnam"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,7,25]]},"reference":[{"key":"2020061010544500800_CIT0001","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S0065-308X(05)61010-X","article-title":"Lymphatic filariasis: treatment, control and elimination","volume":"61","author":"Ottesen","year":"2006","journal-title":"Adv Parasitol"},{"key":"2020061010544500800_CIT0002","author":"World Health Organization"},{"key":"2020061010544500800_CIT0003","article-title":"Global programme to eliminate lymphatic filariasis: progress report 2000\u20132009 and strategic plan 2010\u20132020","author":"World Health Organization","year":"2010"},{"key":"2020061010544500800_CIT0004","first-page":"589","article-title":"Global programme to eliminate lymphatic filariasis: progress report, 2017","volume":"93","author":"World Health Organization","year":"2018","journal-title":"Wkly Epidemiol Rec"},{"key":"2020061010544500800_CIT0005","author":"Global Alliance to Eliminate Lymphatic Filariasis"},{"key":"2020061010544500800_CIT0006","volume-title":"Investing to overcome the global impact of neglected tropical diseases: third WHO report on neglected tropical diseases","author":"World Health Organization","year":"2015"},{"key":"2020061010544500800_CIT0007"},{"key":"2020061010544500800_CIT0008","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0169-4758(00)01643-4","article-title":"The economic burden of lymphatic filariasis in India","volume":"16","author":"Ramaiah","year":"2000","journal-title":"Parasitol Today"},{"key":"2020061010544500800_CIT0009","volume-title":"Cost effectiveness of integrating lymphatic filariasis elimination into APOC onchocerciasis control programs","author":"Haddix","year":"1999"},{"key":"2020061010544500800_CIT0010","doi-asserted-by":"crossref","first-page":"e317","DOI":"10.1371\/journal.pntd.0000317","article-title":"The global programme to eliminate lymphatic filariasis: health impact after 8 years","volume":"2","author":"Ottesen","year":"2008","journal-title":"PLOS Negl Trop Dis"},{"key":"2020061010544500800_CIT0011","doi-asserted-by":"crossref","first-page":"e708","DOI":"10.1371\/journal.pntd.0000708","article-title":"The economic benefits resulting from the first 8 years of the global programme to eliminate lymphatic filariasis (2000\u20132007)","volume":"4","author":"Chu","year":"2010","journal-title":"PLOS Negl Trop Dis"},{"key":"2020061010544500800_CIT0012"},{"key":"2020061010544500800_CIT0013","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1017\/S0031182000066646","article-title":"Re-assessing the global prevalence and distribution of lymphatic filariasis","volume":"112","author":"Michael","year":"1996","journal-title":"Parasitology"},{"key":"2020061010544500800_CIT0014","first-page":"1211","article-title":"Vos T, Abajobir AA, Abbafati C, et al. Global,","volume":"390","year":"2017","journal-title":"Lancet"},{"key":"2020061010544500800_CIT0015","doi-asserted-by":"crossref","first-page":"e3319","DOI":"10.1371\/journal.pntd.0003319","article-title":"Progress and impact of 13 years of the global programme to eliminate lymphatic filariasis on reducing the burden of filarial disease","volume":"8","author":"Ramaiah","year":"2014","journal-title":"PLOS Negl Trop Dis"},{"key":"2020061010544500800_CIT0016","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/S0035-9203(96)90415-0","article-title":"Epidemiology of acute filarial episodes caused by Wuchereria bancrofti infection in two rural villages in Tamil, Nadu, south India","volume":"90","author":"Ramaiah","year":"1996","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2020061010544500800_CIT0017","article-title":"Babu B, Nayak A, Dhal K, Acharya A, Jangid P, Mallick G. The economic loss due to treatment costs and work loss to individuals with chronic lymphatic filariasis in rural communities of Orissa, India. Acta Tropica 2002; 82:31\u20138. doi:10.1016\/S0001-706X(02)00030-X"},{"key":"2020061010544500800_CIT0018","doi-asserted-by":"crossref","first-page":"591","DOI":"10.4269\/ajtmh.1996.54.591","article-title":"The epidemiology of acute adenolymphangitis due to lymphatic filariasis in northern Ghana","volume":"54","author":"Gyapong","year":"1996","journal-title":"Am J Trop Med Hyg"},{"key":"2020061010544500800_CIT0019","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0001-706X(99)00090-X","article-title":"Acute adenolymphangitis due to bancroftian filariasis in Rufiji district, south east Tanzania","volume":"75","author":"Gasarasi","year":"2000","journal-title":"Acta Trop"},{"key":"2020061010544500800_CIT0020","doi-asserted-by":"crossref","first-page":"e0004397","DOI":"10.1371\/journal.pntd.0004397","article-title":"Productivity loss related to neglected tropical diseases eligible for preventive chemotherapy: a systematic literature review","volume":"10","author":"Lenk","year":"2016","journal-title":"PLOS Negl Trop Dis"},{"key":"2020061010544500800_CIT0021","author":"World Bank"},{"key":"2020061010544500800_CIT0022","author":"United States Department of State"},{"key":"2020061010544500800_CIT0023","author":"International Labour Organization"},{"key":"2020061010544500800_CIT0024","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s40273-013-0056-3","article-title":"Productivity costs in economic evaluations: past, present, future","volume":"31","author":"Krol","year":"2013","journal-title":"Pharmacoeconomics"},{"key":"2020061010544500800_CIT0025","doi-asserted-by":"crossref","first-page":"e0005289","DOI":"10.1371\/journal.pntd.0005289","article-title":"The socioeconomic benefit to individuals of achieving the 2020 targets for five preventive chemotherapy neglected tropical diseases","volume":"11","author":"Redekop","year":"2017","journal-title":"PLOS Negl Trop Dis"},{"key":"2020061010544500800_CIT0026","author":"United Nations"},{"key":"2020061010544500800_CIT0027","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/00034983.1996.11813024","article-title":"The economic burden of lymphatic filariasis in northern Ghana","volume":"90","author":"Gyapong","year":"1996","journal-title":"Ann Trop Med Parasitol"},{"key":"2020061010544500800_CIT0028","doi-asserted-by":"crossref","first-page":"877","DOI":"10.4269\/ajtmh.16-0286","article-title":"Economic costs and benefits of a community-based lymphedema management program for lymphatic filariasis in Odisha State, India","volume":"95","author":"Stillwaggon","year":"2016","journal-title":"Am J Trop Med Hyg"},{"key":"2020061010544500800_CIT0029","first-page":"728","article-title":"Investment success in public health: an analysis of the cost-effectiveness and cost-benefit of the Global Programme to Eliminate Lymphatic Filariasis","volume":"64","author":"Turner","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2020061010544500800_CIT0030","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S0035-9203(96)90426-5","article-title":"Impact of lymphatic filariasis on the productivity of male weavers in a south Indian village","volume":"90","author":"Ramu","year":"1996","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"2020061010544500800_CIT0031","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0167-6296(94)00044-5","article-title":"The friction cost method for measuring indirect costs of disease","volume":"14","author":"Koopmanschap","year":"1995","journal-title":"J Health Econ"},{"key":"2020061010544500800_CIT0032","article-title":"Turner HC, Toor J, D\u00e9irdre Hollingsworth T, Anderson RM. Economic evaluations of mass drug administration: The importance of economies of scale and scope. Clin Infect Dis 2017; 66:1298\u2013303. doi:10.1093\/cid\/cix1001"},{"key":"2020061010544500800_CIT0033","author":"Institute for Health Metrics and Evaluation"},{"key":"2020061010544500800_CIT0034"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciz671\/29808300\/ciz671.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/70\/12\/2561\/33375436\/ciz671.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/70\/12\/2561\/33375436\/ciz671.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T12:56:28Z","timestamp":1591793788000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/70\/12\/2561\/5538386"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,25]]},"references-count":34,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2019,7,25]]},"published-print":{"date-parts":[[2020,6,10]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciz671","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,6,15]]},"published":{"date-parts":[[2019,7,25]]}}}